Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03763162 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03763162
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-17
- Primary completion
- 2027-10-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.